Par To Pay $45M For Off-Label Marketing Of AIDS Drug

Law360, New York (March 5, 2013, 2:14 PM EST) -- New Jersey-based Par Pharmaceutical Cos. Inc. agreed Tuesday to pay $45 million to settle civil and criminal claims alleging the company mismarketed its Megace ES AIDS weight-enhancement drug as suitable for non-AIDS geriatric patients without U.S. Food and Drug Administration approval.

Par CEO Paul V. Campanelli pled guilty on behalf of the company to a criminal misdemeanor for misbranding Megace ES in violation of the Federal Food, Drug and Cosmetic Act, federal prosecutors announced. Par will pay $22.5 million under a civil settlement agreement, and will...
To view the full article, register now.